Immunosuppression in Solid-Organ Transplantation: Essentials and Practical Tips
暂无分享,去创建一个
[1] A. Henning,et al. New‐Onset Diabetes After Transplantation: Results From a Double‐Blind Early Corticosteroid Withdrawal Trial , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] Jeong M. Park,et al. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] C. Doligalski,et al. Sublingual Administration of Tacrolimus: Current Trends and Available Evidence , 2014, Pharmacotherapy.
[4] J. Gaynor,et al. Randomized Trial of Three Induction Antibodies in Kidney Transplantation: Long-Term Results , 2014, Transplantation.
[5] D. Rush,et al. Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] A. Israni,et al. OPTN/SRTR 2012 Annual Data Report: Liver , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] V. Hadjianastassiou,et al. Rituximab in renal transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[8] R. Lee,et al. Current trends in immunosuppressive therapies for renal transplant recipients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[9] D. Leeser,et al. Induction Therapy in Renal Transplant Recipients , 2012 .
[10] Junchao Cai,et al. Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data , 2010, Transplantation.
[11] Klemens Budde,et al. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk , 2010, Transplant international : official journal of the European Society for Organ Transplantation.
[12] L. Rostaing,et al. A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] J. Campistol,et al. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] L. Rostaing,et al. Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] E. Woodle,et al. A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy , 2008, Annals of surgery.
[16] Mark J. Thomas,et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids , 2007, Clinical transplantation.
[17] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[18] E. Benedetti,et al. Infectious complications associated with the use of rituximab for ABO‐incompatible and positive cross‐match renal transplant recipients , 2007, Clinical transplantation.
[19] K. Hardinger,et al. Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation , 2006, Pharmacotherapy.
[20] D. Stablein,et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.
[21] R. Wolfe,et al. Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.
[22] M. Marvin,et al. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients , 2003, Transplantation.
[23] J. Fink,et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. , 2001, Transplantation proceedings.
[24] D. Stablein,et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. , 1999, Transplantation.
[25] Barbara B. Hodgson,et al. Nurse's drug handbook , 1993 .
[26] R. Scott,et al. Long-Term Results , 2001 .
[27] G. Klintmalm,et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. , 1980, Surgery, gynecology & obstetrics.